A social project to fight climate change in India begins to yield results
In a small region in India’s technology capital of Bengaluru, social activists, despite initial hesitation from its urban poor, walked into Anjanapura and.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
In a small region in India’s technology capital of Bengaluru, social activists, despite initial hesitation from its urban poor, walked into Anjanapura and.
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.
HQ Team October 19, 2024: The U.S. Food and Drug Administration (FDA) has approved AbbVei’s drug Vyalev for the treatment of advanced Parkinson’s.
HQ Team October 19, 2024: Stealth startup Treeline Biosciences has raised another $421 million, one of the biggest raises of the year in.
HQ Team October 18, 2024: As global greenhouse gas emissions continue to rise there is an urgency to find effective climate intervention solutions..
Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the.
HQ Team October 17, 2024: Extreme weather conditions and the increasing number of natural disaster events have forced China to take steps to.
Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the.
Twenty-four European universities have formed a network to impart skills to 10,000 medical students across undergraduate degree programmes to address current and future.
India’s coronary drug-eluting stent market may grow at a compound annual growth rate of 4% until 2033 on the back of a rise.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com